Evidence map›Paper›PMID 37386273›Full record

ArticlePharmaceutical research2023

N-oxidation Regioselectivity and Risk Prediction Using DFT-ALIE Calculations.

Gabriel A Valdivia-Berroeta, Nina C Gonnella

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gabriel A Valdivia-BerroetaDepartment of Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., P.O. Box 368, Ridgefield, CT, 06877, USA. gabriel.valdivia-berroeta@boehringer-ingelheim.com.ORCID http://orcid.org/0000-0002-3291-8487
Nina C GonnellaDepartment of Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., P.O. Box 368, Ridgefield, CT, 06877, USA. nina.gonnella@boehringer-ingelheim.com.ORCID http://orcid.org/0000-0001-8944-7180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe formation of N-oxide degradants is a major concern in development of new drugs due to potential effects on a compound's pharmacological activity. Such effects include but are not limited to solubility, stability, toxicity, and efficacy. In addition, these chemical transformations can impact physicochemical properties that affect drug manufacturability. Hence identification and control of N-oxide transformations is of critical importance in the development of new therapeutics.

objectiveThis study describes the development of an in-silico approach to identify N-oxide formation in APIs with respect to autoxidation.

methodsAverage Local Ionization Energy (ALIE) calculations were carried out using molecular modeling techniques and application of Density Functional Theory (DFT) at the B3LYP/6-31G(d,p) level of theory. A total of 257 nitrogen atoms and 15 different oxidizable nitrogen types were used in developing this method.

resultsThe results show that ALIE could be reliably used to predict the most susceptible nitrogen for N-oxide formation. A risk scale was developed that rapidly categorizes nitrogen's oxidative vulnerabilities as small, medium, or high.

conclusionsThe developed process presents a powerful tool to identify structural susceptibilities for N-oxidation as well as enabling rapid structure elucidation in resolving potential experimental ambiguities.

Indexed as

NitrogenOxidesDensity Functional TheoryModels, MolecularOxidation-ReductionNitrogenOxidesactive pharmaceutical ingredient (API)average local ionization energy (ALIE)density functional theory (DFT)N-oxiderisk assessment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.